Articles

Poll

Podcasts

Slideshows

Videos

Once-daily VTAMZA delivers week-one sleep gains and lasting itch control in atopic dermatitis, with safety consistent across studies.

What to Expect for Sleep Improvement With Tapinarof in AD, With Druhan Howell, MD

Post hoc pooled data from ADORING 1 and 2 demonstrate statistically significant improvements in patient and family sleep scores in children aged 2–17 years

Tapinarof Cream 1% Improves Sleep in Atopic Dermatitis, With Druhan Howell, MD

Stay updated with the latest healthcare breakthroughs, FDA actions and new phase 2 and 3 data, in this week’s essential news roundup.

The HCPFive: Top News for Healthcare Providers from the Week of 02/08

FDA grants Priority Review for Takeda’s oveporexton, an oral orexin agonist for narcolepsy type 1, showing near-normal symptom control in phase 3.

FDA Accepts NDA, Grants Priority Review for Oveporexton to Treat Narcolepsy Type 1

In a 26-week head-to-head study, adjunctive seltorexant led to less weight gain and improved insulin sensitivity trends compared with quetiapine XR in MDD with insomnia.


Seltorexant Shows Favorable Metabolic Profile, With Celine Goldberger, MD, PhD

The FDA has not approved the sNDA for tasimelteon in jet lag disorder in its current form, citing positive efficacy but limited real-world applicability. 


FDA Denies Tasimelteon’s Supplemental New Drug Application For Jet Lag Disorder

Alixorexton receives FDA Breakthrough Therapy Designation, promising significant advancements in treating narcolepsy type 1.

FDA Grants Breakthrough Therapy Designation to Alixorexton for Narcolepsy Type 1

From FDA decisions to late-phase trial readouts and updated practice guidelines, 2025 delivered clinically actionable insights across sleep conditions.

​​Sleep in 2025: Year in Review

Registry data show worse asthma control, more exacerbations, and higher healthcare utilization in patients with severe asthma and a comorbid sleep disorder.

Sleep Disorders Linked to Poorer Symptom Control in Severe Asthma

Late-breaking data at CHEST 2025 support the novel combination therapy, which may be submitted to the FDA in application for patients with OSA in coming months.

Aroxybutynin and Atomoxetine (AD109) Reduces Obstructive Sleep Apnea Burden in Phase 3 SynAIRgy

Obstructive Sleep Apnea

Insomnia

The HCPLive insomnia page is a comprehensive resource for clinical news and insights on sleeplessness. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for insomnia, and more.

On the HCPLive sleep page, resources on the topics of medical news and expert insight into sleep medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sleep apnea, insomnia, narcolepsy, and more.